Merck & Co., Inc. (Merck) reported a robust financial performance in the second quarter of 2024, with worldwide sales reaching $16.1 billion, a 7% increase compared to the same quarter in 2023. Excluding the impact of foreign exchange, sales grew by 11%. The U.S. market saw a 12% increase in sales, while international sales rose by 3%. The company's growth was primarily driven by higher sales in the oncology franchise, particularly Keytruda and Welireg, as well as increased sales in the vaccines franchise, including Gardasil/Gardasil 9 and Vaxneuvance. However, sales in the diabetes franchise, including Januvia and Janumet, declined due to competitive pressures and pricing challenges. Merck's business development activities included the acquisition of the aqua business of Elanco for $1.3 billion, expanding its Animal Health...Show More

Merck & Co., Inc. (Merck) reported a robust financial performance in the second quarter of 2024, with worldwide sales reaching $16.1 billion, a 7% increase compared to the same quarter in 2023. Excluding the impact of foreign exchange, sales grew by 11%. The U.S. market saw a 12% increase in sales, while international sales rose by 3%. The company's growth was primarily driven by higher sales in the oncology franchise, particularly Keytruda and Welireg, as well as increased sales in the vaccines franchise, including Gardasil/Gardasil 9 and Vaxneuvance. However, sales in the diabetes franchise, including Januvia and Janumet, declined due to competitive pressures and pricing challenges. Merck's business development activities included the acquisition of the aqua business of Elanco for $1.3 billion, expanding its Animal Health's aqua portfolio. Additionally, Merck acquired Eyebiotech Limited for $1.3 billion, with potential milestone payments of $1.7 billion, and entered into a global license agreement with Orion Corporation for opevesostat. The company also acquired Harpoon Therapeutics for $765 million, enhancing its immunotherapy offerings. Looking ahead, Merck anticipates continued pressure on product pricing and market access, with legislative changes potentially affecting sales and profits. Despite these challenges, the company remains committed to strategic initiatives and investment plans to drive future growth.